12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ISIS-SOD1Rx: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 32 familial ALS patients with SOD1 mutations showed that 0.15, 0.5, 1.5 and 3 mg doses of ISIS-SOD1Rx given as a continuous intrathecal infusion over 12 hours were well tolerated with no dose-limiting toxicities...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >